CXW

In the past six months, CoreCivic's stock has experienced several notable events and trends. The company's stock increased by 6.5% to $20.3680 as of early May 2026. CoreCivic reported strong financial results for Q1 2026, with revenue increasing by 25.8% year-over-year to $614.7 million and net income rising to $37.9 million, driven by higher federal revenue from ICE, new and reactivated facilities, and increased per-diem rates. The company also announced a $148 million acquisition of Clinical Solutions Pharmacy and raised its full-year 2026 guidance. A surge in federal detention demand, particularly from ICE, led to the activation of five previously idle facilities, estimated to generate approximately $500 million in annual revenue. However, a decline of roughly 3,000 ICE detainees led to a reduction in the updated 2026 guidance for EPS. CoreCivic's board approved a stock repurchase program on November 10, 2025, authorizing the company to repurchase $200,000,000 in outstanding shares, and in Q1 2026, 2.3 million shares were repurchased for $44.7 million. The company also saw increased leverage, with total debt rising to $1.41 billion.